BRGSF-HISマウスにおいて、腫瘍微小環境の構成は、腫瘍細胞株由来異種移植片のサブタイプおよび腫瘍負荷によって決定される

背景

The relevance of preclinical models has vastly improved with mice bearing a human immune system, especially in the context of immunotherapy. BRGSF (BALB/c Rag2^-/-, IL2R^-/-, SIRP^NOD and Flt3^-/-) is a highly immunodeficient mouse featuring reduced murine myeloid cells. BRGSF mice reconstituted with human cord blood CD34⁺ cells (BRGSF-HIS) develop functional lymphoid and myeloid compartments. This engraftment is stable over a year and mice do not develop GvHD. Additionally, myeloid compartment can be transiently boosted with exogenous human Flt3L injections. In contrary to other models which overexpress human cytokines to develop human myeloid cells, Flt3L-treated BRGSF-HIS mice do not show side effects. BRGSF-HIS mice are permissive to mouse and human cancer cell lines engraftment.

‍